MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:30Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Xanthine oxidase inhibitors]]
			[[Category:Antihyperuricemic agents]]
			[[Category:Antigout agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #45

2026-05-23T03:34:50Z

parser-claude batch MedTemplate pre-fill, Top 300 #45

New page

{{MedTemplate
| generic = Allopurinol
| brand = Zyloprim, Aloprim (IV)
| structure =
| classes = [[:Category:Xanthine_oxidase_inhibitors|Xanthine oxidase inhibitor]], [[:Category:Antihyperuricemic_agents|Antihyperuricemic agent]], [[:Category:Antigout_agents|Antigout agent]]
| uses = <vote slug="chronic-gout-use">Chronic gout</vote>, <vote slug="tumor-lysis-prophylaxis-use">Tumor lysis syndrome prophylaxis</vote>, <vote slug="asymptomatic-hyperuricemia-cv-use">Asymptomatic hyperuricemia (selected high-risk)</vote>, <vote slug="recurrent-urate-nephrolithiasis-use">Recurrent urate nephrolithiasis</vote>
| starting_dose = 100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease)
| preparations = 100 mg, 300 mg tablets; IV 500 mg vial
| fda_max = 800 mg/d (rarely needed)
| pill_id =
| routes = Oral, IV
| onset = Serum urate falls gradually over days to weeks; acute flare prevention requires colchicine cover during initiation
| duration = 24 hours
| halflife = 1-2 hours (parent); 18-30 hours for active metabolite oxypurinol<ref name="zyloprim-label">FDA Prescribing Information, Zyloprim (allopurinol), Casper Pharma, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016084s048lbl.pdf</ref>
| bioavailability = ~80% (oral)<ref name="zyloprim-label" />
| pregnancy = Limited safety data; weigh benefit individually.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="allopurinol-mech-claim">Allopurinol is a purine analog that competitively inhibits xanthine oxidase (and is itself metabolized by the enzyme to oxypurinol, also a xanthine oxidase inhibitor), blocking the conversion of hypoxanthine to xanthine and xanthine to uric acid.</vote> HLA-B*58:01 carriage is strongly associated with severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), with the strongest risk signal in Han Chinese, Thai, and Korean populations; CPIC and several regulators recommend pre-prescription HLA-B*58:01 testing in those populations<ref name="cpic-allopurinol-hla">CPIC Guideline for HLA-B and Allopurinol, 2016 (update). https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/</ref>.
}}

== References ==
<references />

Allopurinol - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #45